[go: up one dir, main page]

CN107916257B - T1脂肪酶突变体和应用 - Google Patents

T1脂肪酶突变体和应用 Download PDF

Info

Publication number
CN107916257B
CN107916257B CN201810017359.8A CN201810017359A CN107916257B CN 107916257 B CN107916257 B CN 107916257B CN 201810017359 A CN201810017359 A CN 201810017359A CN 107916257 B CN107916257 B CN 107916257B
Authority
CN
China
Prior art keywords
gly
leu
ala
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810017359.8A
Other languages
English (en)
Other versions
CN107916257A (zh
Inventor
王方华
王永华
张慧
黄伟谦
蓝东明
杨博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China University of Technology SCUT
Original Assignee
South China University of Technology SCUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China University of Technology SCUT filed Critical South China University of Technology SCUT
Priority to CN201810017359.8A priority Critical patent/CN107916257B/zh
Publication of CN107916257A publication Critical patent/CN107916257A/zh
Application granted granted Critical
Publication of CN107916257B publication Critical patent/CN107916257B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明公开了T1脂肪酶突变体和应用,所述突变体是对序列SEQ ID NO:1中氨基酸取代位置至少发生如下任意一种突变:(1)采用“原始氨基酸‑位置‑替换的氨基酸”表示脂肪酶突变体中单点突变的氨基酸L359S、I362E或V364N;(2)采用氨基酸序列片段置换方式发生突变,将野生型T1的288‑291位氨基酸残基Asn‑Ala‑Phe‑Ser置换成Glu‑Phe‑Thr‑Lys。突变体水解甘油酯的活性有不同程度的提高,分别是野生型T1的6、6、4、6、3、5倍,而突变体的最适反应温度及pH并没有明显变化。本发明所得突变体,更适合生物化工行业的应用,尤其适应用于难熔油脂的改性。

Description

T1脂肪酶突变体和应用
技术领域
本发明属于生物技术领域,具体地说涉及利用分子生物学技术获得催化活性提高的T1脂肪酶突变体。
背景技术
脂肪酶(EC3.1.1.3)即三酰基甘油水解酶,能够催化水解天然油脂生成脂肪酸、甘油和甘油单酯或二酯。脂肪酶参与的催化反应类型广泛,包括催化解脂、酯交换、酯合成等反应,广泛应用于饲料添加剂、油脂加工、食品行业、生物医药、日用化工等领域。耐高温脂肪酶具有更高的最适反应温度,非常适合工业上对难熔油脂的的改性。例如,棕榈硬脂酸甘油酯,该油脂十分廉价,但是含有较高的高热量和饱和脂肪酸,并且熔点高达44-56℃。因此,开发耐高温脂肪酶在该领域具有重要的工业应用价值。T1脂肪酶是来源于嗜热土芽孢杆菌(Geobacillus zalihae strain T1)的耐热性脂肪酶,能较好水解中长链的甘油酯,该耐热脂肪酶T1最适反应温度高达60℃,在油脂改性工业化应用中已证实具有较好的应用前景(J Sci Food Agric 2014;94:1614–1621;Eur.J.Lipid Sci.Technol.2013,115,564–570;中国粮油学报,2017,32(8),63-70)。但是,目前报道的有关耐热脂肪酶T1的酶活力普遍不高,已报道活性最高野生型酶比酶活为2692U/mg,在对该酶的分子改造方面,目前获得活性最好的突变体F176Y的酶活力为3035U/mg(以pNP-C12人工底物测得)(EuropeanJournal of Lipid Science and Technology.2017,119(3),n/a(8)),与其它商品化脂肪酶在酶活力上仍有较大的差距,这无疑增加了生产及使用该脂肪酶制剂的成本投入,严重制约了该酶工业生产应用。筛选获得活力更高的突变体成为将该酶尽快推向工业化应用的必由之路。
蛋白质工程是一种能够改善酶蛋白质特性的可行的方法,借助分子生物学和生物信息学的方法对蛋白进行理性改造和定点突变,从而获得性能提高的酶突变体。由于该方法具有工作量小和获得阳性突变体的概率大的优势,因此被广泛应用于酶分子改造领域。
发明内容
本发明解决的技术问题是提供活性提高的T1脂肪酶突变体。
本发明的技术方案如下:
通过理性设计构建活力提高的脂肪酶突变体。以氨基酸序列为SEQ ID No.1(GenBank:AAO92067.2)的嗜热土芽孢杆菌(Geobacillus zalihae)T1脂肪酶作为出发亲本,通过对其蛋白结构(PDB:2DSN)的分析,选定突变位点并进行突变氨基酸突变计算模拟,最终运用定点突变的方法构建获得脂肪酶突变体。将野生型T1氨基酸序列SEQ ID NO:1中氨基酸取代位置发生突变,采用“原始氨基酸-位置-替换的氨基酸”来表示脂肪酶突变体中单点突变的氨基酸,所述前3种耐热T1脂肪酶突变体为:T1L359S、T1I362E和T1V364N。第四种突变体采用氨基酸序列片段置换方式发生突变,将野生型T1的288-291位氨基酸残基Asn-Ala-Phe-Ser置换成Glu-Phe-Thr-Lys,该突变体表示为:T1S288-291。第五种突变体为双突变体,在第四种突变体T1S288-291基础上对359位Leu突变为Ser,该突变体表示为:T1S288-291-L359S。第六种突变体T1S288-291-L359S-V364N为在第五种突变体的基础上引入V364N所得的三突变。
上述六种突变体的氨基酸序列分别为SEQ NO.2,SEQ NO.3,SEQ NO.4,SEQ NO.5,SEQ NO.6和SEQ NO.7。
六种突变体的DNA序列分别为SEQ NO.9,SEQ NO.10,SEQ NO.11,SEQ NO.12,SEQNO.13和SEQ NO.14。
所述六种耐热T1脂肪酶突变体基因重组表达质粒及菌株的构建方法,具体步骤如下:
(1)六种耐热T1脂肪酶突变体表达质粒的构建
前四种突变体采用一步PCR扩增全长质粒的定点突变方法进行突变,首先以野生型T1重组表达质粒pET23a-CBD-T1作为模板,分别以前四种突变体对应的突变引物对(T1-L359S-F/T1-L359S-R等)进行PCR扩增,扩增产物即含有引入相应突变位点T1基因序列的pET23a-CBD-T1突变体重组表达质粒。
将上述扩增基因PCR产物经DpnI酶切消化,转化至大肠杆菌E.coli DH5α感受态细胞,测序验证得到突变体重组表达质粒;
第五种突变体T1S288-291-L359S重组表达质粒,是在获得第四种突变体T1S288-291重组表达质粒之后,按照上述方法,以第一种突变体L359S引物对作为扩增引物,以第四种突变体T1S288-291质粒作为模板进行一步PCR获得。
第六种突变体T1S288-291-L359S-V364N重组表达质粒,是在获得第四种突变体T1S288-291重组表达质粒之后,按照上述方法,先以第三种突变体V364N引物对引物对作为扩增引物,以第四种突变体T1S288-291重组表达质粒作为模板进行一步PCR,所得产物经纯化后进一步作为模板,以第一种突变体L359S引物对作为扩增引物进行第二轮PCR之后获得。
(2)利用突变体表达质粒制备重组菌株:
将步骤(1)的突变体表达质粒用CaCl2转化法转化表达宿主菌大肠杆菌BL21(DE3)感受态细胞;将转化液涂布于含有100μg/ml氨苄青霉素LB平板中,37℃培养12h,平板上长出大肠杆菌单菌落为重组菌株;
步骤(1)所述各个突变体对应引物序列如下:
T1-L359S-F 5'-GATATGGGAACGTACAACGTTGACCATTCTGAAATCATCG-3'
T1-L359S-R 5'-CGGATTCGGGTCAACGCCGATGATTTCAGAATGGTCAACGT-3'
T1-I362E-F 5'-GTTGACCATTTGGAAATCGAAGGCGTTGACCCGAATCC-3'
T1-I362E-R 5'-GGATTCGGGTCAACGCCTTCGATTTCCAAATGGTCAAC-3'
T1-V364N-F 5'-CCATTTGGAAATCATCGGCAATGACCCGAATCCGTCATTTG-3'
T1-V364N-R 5'-CAAATGACGGATTCGGGTCATTGCCGATGATTTCCAAATGG-3'
T1-S288-291-F
5'-CTCACAGGCAACCATTATCCCGAACTCGGAATGGAATTTACCAAAGCGGT-3'
T1-S288-291-R
5'-TACGAACCGAGAAACGGAGCGCATACGACCGCTTTGGTAAATTCCATTCCG-3'
本发明涉及脂肪酶突变体重组表达菌株的的构建方法中,可以采用任何适当的载体。适当的载体包括但不限于原核表达载体pET23a、pFL-B62cl、pFL-B13cl、pET28、pET22等;包括但不限于真核表达载体pPIC9K、pPICZα、pPIC3.5K、pPICZ、pYDI或pLIZG7等。
在本发明涉及制备脂肪酶突变体的方法中,所获得的脂肪酶突变体基因可以在原核细胞或真核细胞内表达,所述原核细胞包括但不限于大肠杆菌、枯草芽抱杆菌、链霉菌。所述真核细胞包括但不限于毕赤巴斯德酵母、酿酒酵母和黑曲霉,也可以采用本领域已知的任何其它适当方法实现在原核细胞或真核细胞胞外表达。
以构建得到重组质粒获得的重组大肠杆菌表达菌株为发酵菌株进行液体发酵,制备重组脂肪酶。以橄榄油乳化法测定突变体的酶活力及最适反应温度,T1L359S,T1I362E,T1V364N,T1S288-291,T1S288-291-L359S和T1S288-291-L359S-V364N突变体的酶活较野生型分别提高了6、6、4、6、3、5倍,同时最适反应温度和pH与野生型保持不变。
所述的脂肪酶突变体可应用于洗涤剂、添加剂、食品、制药、造纸或生物能源等工业生产中。
与现有技术相比,本发明具有如下有益效果:
本发明所得突变体T1L359S,T1I362E,T1V364N,T1S288-291和T1S288-291-L359ST1S288-291-L359S-V364N为耐热T1脂肪酶水解活性提高的突变体,同时,其最适反应温度和pH未发生改变。经改造后的T1L359S,T1I362E,T1V364N,T1S288-291和T1S288-291-L359S、T1S288-291-L359S-V364N突变体水解活性有不同程度的提高,分别是野生型的T1脂肪酶的6、6、4、6、3、5倍,更适合生物化工行业的应用,尤其适应用于难熔油脂的改性。
附图说明
图1为脂肪酶T1及突变体的蛋白纯化图,Marker泳道是蛋白分子量Marker,泳道1-7是纯化后的野生型T1、T1L359S,T1I362E,T1V364N,T1S288-291,T1S288-291-L359S和T1S288-291-L359S-V364N。
图2为脂肪酶T1及突变体的最适反应温度测定结果图。
图3为脂肪酶T1及突变体的最适反应pH测定结果图。
图4为脂肪酶T1及突变体的相对脂肪酶活力结果图,以野生型(WT)活力为100%。
具体实施方式
下面结合具体实施例对本发明作进一步具体详细描述,但本发明的实施方式不限于此,对于未特别注明的工艺参数,可参照常规技术进行。
实施例1:T1脂肪酶野生型大肠杆菌表达载体的构建
根据Genbank的嗜热地芽孢杆菌(Geobacillus zalihae)耐热T1脂肪酶氨基酸序列(GenBank:AAO92067.2),通过信号肽预测分析软件,对其信号肽进行准确预测并从完整序列中进行删除,获得脂肪酶GZEL成熟肽编码序列,其氨基酸序列如SEQ ID NO.1所示;委托上海生工生物工程公司根据大肠杆菌码子偏好性对序列进行优化,同时,在其上下游分别引入KpnI和XhoI酶切位点,利用人工合成的方法合成编码该氨基酸序列的基因。基因合成后,基因产物经DNA纯化试剂盒纯化后,限制性内切酶KpnI和XhoI分别对纯化的基因片段和质粒pET23a-CBD进行双酶切消化,连接,转化至大肠杆菌E.coli DH5α感受态细胞。涂布于LB(含100ug/mL氨苄青霉素)平板。挑取阳性克隆通过Kpn I和XhoI双酶切鉴定及基因测序,结果表明获得了野生型pET23a-CBD-T1表达质粒。
实施例2:T1脂肪酶氨基酸位点突变体的构建
采用定点突变技术构建突变体T1L359S、T1I362E、T1V364N和T1S288-291,一步PCR方法引入目的突变位点,以T1野生型基因pET23a-CBD-T1为模板,分别使用前4种突变体对应的突变引物对(T1-L359S-F/T1-L359S-R等)进行PCR反应,定点突变反应条件:
Figure BDA0001542379520000041
Figure BDA0001542379520000051
使用的引物,见下表:
Figure BDA0001542379520000052
PCR扩增条件:94℃3min;98℃10s,58℃15s,72℃5min,30个循环;72℃10min。
PCR扩增产物接着用DpnI酶37℃酶切消化2h,DpnI酶切反应条件:
Figure BDA0001542379520000053
以酶切产物转化至大肠杆菌E.coli DH5α感受态细胞。涂布于LB(含100ug/mL氨苄青霉素)平板。生长12h后,挑取平板上10个单菌落进行菌落PCR,挑取阳性克隆通过基因测序,结果表明获得了正确的突变表达质粒pET23a-CBD-T1-L359S、pET23a-CBD-T1-I362E、pET23a-CBD-T1-V364N和pET23a-CBD-T1-S288-291。
第五种突变体T1S288-291-L359S的重组表达质粒,是在获得第四种突变体T1S288-291重组表达质粒之后,按照上述方法,以第一种突变体L359S引物对(T1-L359S-F/T1-L359S-R),第四种突变体pET23a-CBD-T1S288-291质粒作为模板进行一步PCR之后获得。
第六种突变体T1S288-291-L359S-V364N重组表达质粒,是在获得第四种突变体T1S288-291重组表达质粒之后,按照上述方法,先以第三种突变体V364N引物对引物对作为扩增引物,以第四种突变体T1S288-291重组表达质粒作为模板进行一步PCR,所得产物经纯化后进一步作为模板,以第一种突变体L359S引物对作为扩增引物进行第二轮PCR之后获得。
实施例3:脂肪酶T1及其突变体的重组表达及纯化
将突变体表达质粒转化至E.coli BL21(DE3)感受态细胞。涂布于LB(含100μg/mL氨苄青霉素)平板。生长15h后,挑取平板上10个单菌落进行菌落PCR,挑取阳性克隆通过基因测序,结果表明获得了正确的T1-L359S、T1-I362E、T1-V364N、T1-S288-291、T1S288-291-L359S和T1S288-291-L359S-V364N突变体阳性大肠杆菌BL21(DE3)菌株。
将野生型T1表达菌株以及各T1脂肪酶突变体菌株,接种至5ml LB(含100μg/mL氨苄青霉素)培养基中,37℃,200rpm振荡培养12h后,取2ml菌液接种200mL LB(含100μg/mL氨苄青霉素)培养基,20℃,200rpm振荡培养至OD600=0.6,加入40μL 1M IPTG诱导表达,20℃,200rpm振荡培养30h。收集T1野生型及其突变体菌株发酵的菌体。用原发酵液体积40%的PBS缓冲液(137mM NaCl,2.7mMKCl,10mMNa2HPO4,2mMKH2PO4,pH7.4)重悬菌体,超声破碎10min。11000g,10min,4℃离心收集破碎后的上清液,接着上清液用0.22μm的滤膜抽滤。滤过上清液上样镍柱亲和层析柱,层析柱首先用Tris-HCl(pH8.0)缓冲液进行平衡,流速4mL/min,平衡结束后进行蛋白上样,最后用含500mM咪唑的Tris-HCl(pH8.0)缓冲液进行梯度洗脱,目标蛋白在100mM咪唑浓度处被洗脱下来。将洗脱下来的目的蛋白进一步过G-25脱盐柱脱除咪唑,利用SDS-PAGE电泳对洗脱纯化的重组蛋白进行纯度鉴定(见附图1)。
实施例4:脂肪酶T1及其突变体的活力测定
野生型脂肪酶GZEL及突变体脂肪酶活力的测定均采用橄榄油乳化法测得。橄榄油底物乳化液:按橄榄油与4%聚乙烯醇溶液体积比为1:3的比例,将定量橄榄油加入至一定量4%聚乙烯醇溶液中,用高速均质机均质,均质完全后使用。脂肪酶活力定义为:在特定温度与pH条件下,每分钟内蛋白酶催化水解橄榄油底物乳化液底物产生1微摩尔(μmoL)游离脂肪酸所需的酶量即为一个脂肪酶活力单位。用U表示。
脂肪酶酶活测定条件:1ml酶液+4ml底物(橄榄油乳化液)+5ml 50mM Tris-HCLBuffer pH 9.0,60℃水浴摇床反应15min。然后加入10mL 95%乙醇终止反应,再加入2滴酚酞,用50mM NaOH进行滴定,记录消耗50mM NaOH溶液体积ΔV(NaOH)。酶活力计算公式如下:酶活(U/mL)=50×ΔV(NaOH)/15。
(1)酶最适反应温度测定
野生型及突变体脂肪酶的最适反应温度条件测定方法如下:按照上述脂肪酶活力的测定方法,固定反应体系pH为9.0条件下,以橄榄油底物乳化液为底物,加入相对应pH值的缓冲液,将反应体系置于不同温度条件下反应(30.0℃~80.0℃),测定不同反应温度条件下突变体及野生型酶液的脂肪酶活力。对照组和样品组均做三组平行。以各自活力最高点为100%,计算不同温度条件下脂肪酶的相对酶活。以温度设定值为横坐标,相对活力为纵坐标作图。结果如图2所示,野生型及各突变体T1脂肪酶的最适反应温度均为60℃,未发生明显改变。
(2)酶最适反应pH测定
野生型及突变体脂肪酶活力的最适反应pH条件的测定方法如下:按照以上的脂肪酶活力的测定方法,固定反应温度条件为60℃,以橄榄油底物乳化液为底物,加入不同pH值的缓冲液(4.0~8.0)(不同pH缓冲液:pH 5.0,0.05M柠檬酸-0.05M柠檬酸钠;pH6.0-7.0,0.05M磷酸二氢钠-0.05M磷酸氢二钠;pH8.0-9.0,0.05M Tris-HCl;pH 10.0,0.05M Gly-NaOH),使酶在不同pH环境条件下进行反应,测定不同pH环境条件下各突变体酶液的脂肪酶活力。对照组和样品组均做三组平行。以pH值为横坐标,对应的酶比活力为纵坐标作图。以活力最高点为100%,计算不同pH条件下脂肪酶的相对酶活。结果如图3所示,野生型T1脂肪酶与各突变体的最适作用pH均为9.0,位点突变未造成最适反应pH的改变。
如图4所示,在最适反应温度和最适反应pH的条件下,各突变体的活力比野生型分别提高了6、6、4、6、3、5倍。
综上所述,与野生型相比,本发明获得的脂肪酶突变体在没有改变其最适作用温度及pH的情况下,显著提高了其自身酶活力,更适合应用于洗涤剂、添加剂、食品、制药、造纸、或生物能源等工业领域,具有广阔的市场空间。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
序列表
<110> 华南理工大学
<120> T1脂肪酶突变体和应用
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 388
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ala Ser Leu Arg Ala Asn Asp Ala Pro Ile Val Leu Leu His Gly Phe
1 5 10 15
Thr Gly Trp Gly Arg Glu Glu Met Phe Gly Phe Lys Tyr Trp Gly Gly
20 25 30
Val Arg Gly Asp Ile Glu Gln Trp Leu Asn Asp Asn Gly Tyr Arg Thr
35 40 45
Tyr Thr Leu Ala Val Gly Pro Leu Ser Ser Asn Trp Asp Arg Ala Cys
50 55 60
Glu Ala Tyr Ala Gln Leu Val Gly Gly Thr Val Asp Tyr Gly Ala Ala
65 70 75 80
His Ala Ala Lys His Gly His Ala Arg Phe Gly Arg Thr Tyr Pro Gly
85 90 95
Leu Leu Pro Glu Leu Lys Arg Gly Gly Arg Ile His Ile Ile Ala His
100 105 110
Ser Gln Gly Gly Gln Thr Ala Arg Met Leu Val Ser Leu Leu Glu Asn
115 120 125
Gly Ser Gln Glu Glu Arg Glu Tyr Ala Lys Ala His Asn Val Ser Leu
130 135 140
Ser Pro Leu Phe Glu Gly Gly His His Phe Val Leu Ser Val Thr Thr
145 150 155 160
Ile Ala Thr Pro His Asp Gly Thr Thr Leu Val Asn Met Val Asp Phe
165 170 175
Thr Asp Arg Phe Phe Asp Leu Gln Lys Ala Val Leu Glu Ala Ala Ala
180 185 190
Val Ala Ser Asn Val Pro Tyr Thr Ser Gln Val Tyr Asp Phe Lys Leu
195 200 205
Asp Gln Trp Gly Leu Arg Arg Gln Pro Gly Glu Ser Phe Asp His Tyr
210 215 220
Phe Glu Arg Leu Lys Arg Ser Pro Val Trp Thr Ser Thr Asp Thr Ala
225 230 235 240
Arg Tyr Asp Leu Ser Val Ser Gly Ala Glu Lys Leu Asn Gln Trp Val
245 250 255
Gln Ala Ser Pro Asn Thr Tyr Tyr Leu Ser Phe Ser Thr Glu Arg Thr
260 265 270
Tyr Arg Gly Ala Leu Thr Gly Asn His Tyr Pro Glu Leu Gly Met Asn
275 280 285
Ala Phe Ser Ala Val Val Cys Ala Pro Phe Leu Gly Ser Tyr Arg Asn
290 295 300
Pro Thr Leu Gly Ile Asp Asp Arg Trp Leu Glu Asn Asp Gly Ile Val
305 310 315 320
Asn Thr Val Ser Met Asn Gly Pro Lys Arg Gly Ser Ser Asp Arg Ile
325 330 335
Val Pro Tyr Asp Gly Thr Leu Lys Lys Gly Val Trp Asn Asp Met Gly
340 345 350
Thr Tyr Asn Val Asp His Leu Glu Ile Ile Gly Val Asp Pro Asn Pro
355 360 365
Ser Phe Asp Ile Arg Ala Phe Tyr Leu Arg Leu Ala Glu Gln Leu Ala
370 375 380
Ser Leu Gln Pro
385
<210> 2
<211> 388
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Ala Ser Leu Arg Ala Asn Asp Ala Pro Ile Val Leu Leu His Gly Phe
1 5 10 15
Thr Gly Trp Gly Arg Glu Glu Met Phe Gly Phe Lys Tyr Trp Gly Gly
20 25 30
Val Arg Gly Asp Ile Glu Gln Trp Leu Asn Asp Asn Gly Tyr Arg Thr
35 40 45
Tyr Thr Leu Ala Val Gly Pro Leu Ser Ser Asn Trp Asp Arg Ala Cys
50 55 60
Glu Ala Tyr Ala Gln Leu Val Gly Gly Thr Val Asp Tyr Gly Ala Ala
65 70 75 80
His Ala Ala Lys His Gly His Ala Arg Phe Gly Arg Thr Tyr Pro Gly
85 90 95
Leu Leu Pro Glu Leu Lys Arg Gly Gly Arg Ile His Ile Ile Ala His
100 105 110
Ser Gln Gly Gly Gln Thr Ala Arg Met Leu Val Ser Leu Leu Glu Asn
115 120 125
Gly Ser Gln Glu Glu Arg Glu Tyr Ala Lys Ala His Asn Val Ser Leu
130 135 140
Ser Pro Leu Phe Glu Gly Gly His His Phe Val Leu Ser Val Thr Thr
145 150 155 160
Ile Ala Thr Pro His Asp Gly Thr Thr Leu Val Asn Met Val Asp Phe
165 170 175
Thr Asp Arg Phe Phe Asp Leu Gln Lys Ala Val Leu Glu Ala Ala Ala
180 185 190
Val Ala Ser Asn Val Pro Tyr Thr Ser Gln Val Tyr Asp Phe Lys Leu
195 200 205
Asp Gln Trp Gly Leu Arg Arg Gln Pro Gly Glu Ser Phe Asp His Tyr
210 215 220
Phe Glu Arg Leu Lys Arg Ser Pro Val Trp Thr Ser Thr Asp Thr Ala
225 230 235 240
Arg Tyr Asp Leu Ser Val Ser Gly Ala Glu Lys Leu Asn Gln Trp Val
245 250 255
Gln Ala Ser Pro Asn Thr Tyr Tyr Leu Ser Phe Ser Thr Glu Arg Thr
260 265 270
Tyr Arg Gly Ala Leu Thr Gly Asn His Tyr Pro Glu Leu Gly Met Asn
275 280 285
Ala Phe Ser Ala Val Val Cys Ala Pro Phe Leu Gly Ser Tyr Arg Asn
290 295 300
Pro Thr Leu Gly Ile Asp Asp Arg Trp Leu Glu Asn Asp Gly Ile Val
305 310 315 320
Asn Thr Val Ser Met Asn Gly Pro Lys Arg Gly Ser Ser Asp Arg Ile
325 330 335
Val Pro Tyr Asp Gly Thr Leu Lys Lys Gly Val Trp Asn Asp Met Gly
340 345 350
Thr Tyr Asn Val Asp His Ser Glu Ile Ile Gly Val Asp Pro Asn Pro
355 360 365
Ser Phe Asp Ile Arg Ala Phe Tyr Leu Arg Leu Ala Glu Gln Leu Ala
370 375 380
Ser Leu Gln Pro
385
<210> 3
<211> 388
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Ala Ser Leu Arg Ala Asn Asp Ala Pro Ile Val Leu Leu His Gly Phe
1 5 10 15
Thr Gly Trp Gly Arg Glu Glu Met Phe Gly Phe Lys Tyr Trp Gly Gly
20 25 30
Val Arg Gly Asp Ile Glu Gln Trp Leu Asn Asp Asn Gly Tyr Arg Thr
35 40 45
Tyr Thr Leu Ala Val Gly Pro Leu Ser Ser Asn Trp Asp Arg Ala Cys
50 55 60
Glu Ala Tyr Ala Gln Leu Val Gly Gly Thr Val Asp Tyr Gly Ala Ala
65 70 75 80
His Ala Ala Lys His Gly His Ala Arg Phe Gly Arg Thr Tyr Pro Gly
85 90 95
Leu Leu Pro Glu Leu Lys Arg Gly Gly Arg Ile His Ile Ile Ala His
100 105 110
Ser Gln Gly Gly Gln Thr Ala Arg Met Leu Val Ser Leu Leu Glu Asn
115 120 125
Gly Ser Gln Glu Glu Arg Glu Tyr Ala Lys Ala His Asn Val Ser Leu
130 135 140
Ser Pro Leu Phe Glu Gly Gly His His Phe Val Leu Ser Val Thr Thr
145 150 155 160
Ile Ala Thr Pro His Asp Gly Thr Thr Leu Val Asn Met Val Asp Phe
165 170 175
Thr Asp Arg Phe Phe Asp Leu Gln Lys Ala Val Leu Glu Ala Ala Ala
180 185 190
Val Ala Ser Asn Val Pro Tyr Thr Ser Gln Val Tyr Asp Phe Lys Leu
195 200 205
Asp Gln Trp Gly Leu Arg Arg Gln Pro Gly Glu Ser Phe Asp His Tyr
210 215 220
Phe Glu Arg Leu Lys Arg Ser Pro Val Trp Thr Ser Thr Asp Thr Ala
225 230 235 240
Arg Tyr Asp Leu Ser Val Ser Gly Ala Glu Lys Leu Asn Gln Trp Val
245 250 255
Gln Ala Ser Pro Asn Thr Tyr Tyr Leu Ser Phe Ser Thr Glu Arg Thr
260 265 270
Tyr Arg Gly Ala Leu Thr Gly Asn His Tyr Pro Glu Leu Gly Met Asn
275 280 285
Ala Phe Ser Ala Val Val Cys Ala Pro Phe Leu Gly Ser Tyr Arg Asn
290 295 300
Pro Thr Leu Gly Ile Asp Asp Arg Trp Leu Glu Asn Asp Gly Ile Val
305 310 315 320
Asn Thr Val Ser Met Asn Gly Pro Lys Arg Gly Ser Ser Asp Arg Ile
325 330 335
Val Pro Tyr Asp Gly Thr Leu Lys Lys Gly Val Trp Asn Asp Met Gly
340 345 350
Thr Tyr Asn Val Asp His Leu Glu Ile Glu Gly Val Asp Pro Asn Pro
355 360 365
Ser Phe Asp Ile Arg Ala Phe Tyr Leu Arg Leu Ala Glu Gln Leu Ala
370 375 380
Ser Leu Gln Pro
385
<210> 4
<211> 388
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Ala Ser Leu Arg Ala Asn Asp Ala Pro Ile Val Leu Leu His Gly Phe
1 5 10 15
Thr Gly Trp Gly Arg Glu Glu Met Phe Gly Phe Lys Tyr Trp Gly Gly
20 25 30
Val Arg Gly Asp Ile Glu Gln Trp Leu Asn Asp Asn Gly Tyr Arg Thr
35 40 45
Tyr Thr Leu Ala Val Gly Pro Leu Ser Ser Asn Trp Asp Arg Ala Cys
50 55 60
Glu Ala Tyr Ala Gln Leu Val Gly Gly Thr Val Asp Tyr Gly Ala Ala
65 70 75 80
His Ala Ala Lys His Gly His Ala Arg Phe Gly Arg Thr Tyr Pro Gly
85 90 95
Leu Leu Pro Glu Leu Lys Arg Gly Gly Arg Ile His Ile Ile Ala His
100 105 110
Ser Gln Gly Gly Gln Thr Ala Arg Met Leu Val Ser Leu Leu Glu Asn
115 120 125
Gly Ser Gln Glu Glu Arg Glu Tyr Ala Lys Ala His Asn Val Ser Leu
130 135 140
Ser Pro Leu Phe Glu Gly Gly His His Phe Val Leu Ser Val Thr Thr
145 150 155 160
Ile Ala Thr Pro His Asp Gly Thr Thr Leu Val Asn Met Val Asp Phe
165 170 175
Thr Asp Arg Phe Phe Asp Leu Gln Lys Ala Val Leu Glu Ala Ala Ala
180 185 190
Val Ala Ser Asn Val Pro Tyr Thr Ser Gln Val Tyr Asp Phe Lys Leu
195 200 205
Asp Gln Trp Gly Leu Arg Arg Gln Pro Gly Glu Ser Phe Asp His Tyr
210 215 220
Phe Glu Arg Leu Lys Arg Ser Pro Val Trp Thr Ser Thr Asp Thr Ala
225 230 235 240
Arg Tyr Asp Leu Ser Val Ser Gly Ala Glu Lys Leu Asn Gln Trp Val
245 250 255
Gln Ala Ser Pro Asn Thr Tyr Tyr Leu Ser Phe Ser Thr Glu Arg Thr
260 265 270
Tyr Arg Gly Ala Leu Thr Gly Asn His Tyr Pro Glu Leu Gly Met Asn
275 280 285
Ala Phe Ser Ala Val Val Cys Ala Pro Phe Leu Gly Ser Tyr Arg Asn
290 295 300
Pro Thr Leu Gly Ile Asp Asp Arg Trp Leu Glu Asn Asp Gly Ile Val
305 310 315 320
Asn Thr Val Ser Met Asn Gly Pro Lys Arg Gly Ser Ser Asp Arg Ile
325 330 335
Val Pro Tyr Asp Gly Thr Leu Lys Lys Gly Val Trp Asn Asp Met Gly
340 345 350
Thr Tyr Asn Val Asp His Leu Glu Ile Ile Gly Asn Asp Pro Asn Pro
355 360 365
Ser Phe Asp Ile Arg Ala Phe Tyr Leu Arg Leu Ala Glu Gln Leu Ala
370 375 380
Ser Leu Gln Pro
385
<210> 5
<211> 388
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Ala Ser Leu Arg Ala Asn Asp Ala Pro Ile Val Leu Leu His Gly Phe
1 5 10 15
Thr Gly Trp Gly Arg Glu Glu Met Phe Gly Phe Lys Tyr Trp Gly Gly
20 25 30
Val Arg Gly Asp Ile Glu Gln Trp Leu Asn Asp Asn Gly Tyr Arg Thr
35 40 45
Tyr Thr Leu Ala Val Gly Pro Leu Ser Ser Asn Trp Asp Arg Ala Cys
50 55 60
Glu Ala Tyr Ala Gln Leu Val Gly Gly Thr Val Asp Tyr Gly Ala Ala
65 70 75 80
His Ala Ala Lys His Gly His Ala Arg Phe Gly Arg Thr Tyr Pro Gly
85 90 95
Leu Leu Pro Glu Leu Lys Arg Gly Gly Arg Ile His Ile Ile Ala His
100 105 110
Ser Gln Gly Gly Gln Thr Ala Arg Met Leu Val Ser Leu Leu Glu Asn
115 120 125
Gly Ser Gln Glu Glu Arg Glu Tyr Ala Lys Ala His Asn Val Ser Leu
130 135 140
Ser Pro Leu Phe Glu Gly Gly His His Phe Val Leu Ser Val Thr Thr
145 150 155 160
Ile Ala Thr Pro His Asp Gly Thr Thr Leu Val Asn Met Val Asp Phe
165 170 175
Thr Asp Arg Phe Phe Asp Leu Gln Lys Ala Val Leu Glu Ala Ala Ala
180 185 190
Val Ala Ser Asn Val Pro Tyr Thr Ser Gln Val Tyr Asp Phe Lys Leu
195 200 205
Asp Gln Trp Gly Leu Arg Arg Gln Pro Gly Glu Ser Phe Asp His Tyr
210 215 220
Phe Glu Arg Leu Lys Arg Ser Pro Val Trp Thr Ser Thr Asp Thr Ala
225 230 235 240
Arg Tyr Asp Leu Ser Val Ser Gly Ala Glu Lys Leu Asn Gln Trp Val
245 250 255
Gln Ala Ser Pro Asn Thr Tyr Tyr Leu Ser Phe Ser Thr Glu Arg Thr
260 265 270
Tyr Arg Gly Ala Leu Thr Gly Asn His Tyr Pro Glu Leu Gly Met Glu
275 280 285
Phe Thr Lys Ala Val Val Cys Ala Pro Phe Leu Gly Ser Tyr Arg Asn
290 295 300
Pro Thr Leu Gly Ile Asp Asp Arg Trp Leu Glu Asn Asp Gly Ile Val
305 310 315 320
Asn Thr Val Ser Met Asn Gly Pro Lys Arg Gly Ser Ser Asp Arg Ile
325 330 335
Val Pro Tyr Asp Gly Thr Leu Lys Lys Gly Val Trp Asn Asp Met Gly
340 345 350
Thr Tyr Asn Val Asp His Leu Glu Ile Ile Gly Val Asp Pro Asn Pro
355 360 365
Ser Phe Asp Ile Arg Ala Phe Tyr Leu Arg Leu Ala Glu Gln Leu Ala
370 375 380
Ser Leu Gln Pro
385
<210> 6
<211> 388
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Ala Ser Leu Arg Ala Asn Asp Ala Pro Ile Val Leu Leu His Gly Phe
1 5 10 15
Thr Gly Trp Gly Arg Glu Glu Met Phe Gly Phe Lys Tyr Trp Gly Gly
20 25 30
Val Arg Gly Asp Ile Glu Gln Trp Leu Asn Asp Asn Gly Tyr Arg Thr
35 40 45
Tyr Thr Leu Ala Val Gly Pro Leu Ser Ser Asn Trp Asp Arg Ala Cys
50 55 60
Glu Ala Tyr Ala Gln Leu Val Gly Gly Thr Val Asp Tyr Gly Ala Ala
65 70 75 80
His Ala Ala Lys His Gly His Ala Arg Phe Gly Arg Thr Tyr Pro Gly
85 90 95
Leu Leu Pro Glu Leu Lys Arg Gly Gly Arg Ile His Ile Ile Ala His
100 105 110
Ser Gln Gly Gly Gln Thr Ala Arg Met Leu Val Ser Leu Leu Glu Asn
115 120 125
Gly Ser Gln Glu Glu Arg Glu Tyr Ala Lys Ala His Asn Val Ser Leu
130 135 140
Ser Pro Leu Phe Glu Gly Gly His His Phe Val Leu Ser Val Thr Thr
145 150 155 160
Ile Ala Thr Pro His Asp Gly Thr Thr Leu Val Asn Met Val Asp Phe
165 170 175
Thr Asp Arg Phe Phe Asp Leu Gln Lys Ala Val Leu Glu Ala Ala Ala
180 185 190
Val Ala Ser Asn Val Pro Tyr Thr Ser Gln Val Tyr Asp Phe Lys Leu
195 200 205
Asp Gln Trp Gly Leu Arg Arg Gln Pro Gly Glu Ser Phe Asp His Tyr
210 215 220
Phe Glu Arg Leu Lys Arg Ser Pro Val Trp Thr Ser Thr Asp Thr Ala
225 230 235 240
Arg Tyr Asp Leu Ser Val Ser Gly Ala Glu Lys Leu Asn Gln Trp Val
245 250 255
Gln Ala Ser Pro Asn Thr Tyr Tyr Leu Ser Phe Ser Thr Glu Arg Thr
260 265 270
Tyr Arg Gly Ala Leu Thr Gly Asn His Tyr Pro Glu Leu Gly Met Glu
275 280 285
Phe Thr Lys Ala Val Val Cys Ala Pro Phe Leu Gly Ser Tyr Arg Asn
290 295 300
Pro Thr Leu Gly Ile Asp Asp Arg Trp Leu Glu Asn Asp Gly Ile Val
305 310 315 320
Asn Thr Val Ser Met Asn Gly Pro Lys Arg Gly Ser Ser Asp Arg Ile
325 330 335
Val Pro Tyr Asp Gly Thr Leu Lys Lys Gly Val Trp Asn Asp Met Gly
340 345 350
Thr Tyr Asn Val Asp His Ser Glu Ile Ile Gly Val Asp Pro Asn Pro
355 360 365
Ser Phe Asp Ile Arg Ala Phe Tyr Leu Arg Leu Ala Glu Gln Leu Ala
370 375 380
Ser Leu Gln Pro
385
<210> 7
<211> 388
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Ala Ser Leu Arg Ala Asn Asp Ala Pro Ile Val Leu Leu His Gly Phe
1 5 10 15
Thr Gly Trp Gly Arg Glu Glu Met Phe Gly Phe Lys Tyr Trp Gly Gly
20 25 30
Val Arg Gly Asp Ile Glu Gln Trp Leu Asn Asp Asn Gly Tyr Arg Thr
35 40 45
Tyr Thr Leu Ala Val Gly Pro Leu Ser Ser Asn Trp Asp Arg Ala Cys
50 55 60
Glu Ala Tyr Ala Gln Leu Val Gly Gly Thr Val Asp Tyr Gly Ala Ala
65 70 75 80
His Ala Ala Lys His Gly His Ala Arg Phe Gly Arg Thr Tyr Pro Gly
85 90 95
Leu Leu Pro Glu Leu Lys Arg Gly Gly Arg Ile His Ile Ile Ala His
100 105 110
Ser Gln Gly Gly Gln Thr Ala Arg Met Leu Val Ser Leu Leu Glu Asn
115 120 125
Gly Ser Gln Glu Glu Arg Glu Tyr Ala Lys Ala His Asn Val Ser Leu
130 135 140
Ser Pro Leu Phe Glu Gly Gly His His Phe Val Leu Ser Val Thr Thr
145 150 155 160
Ile Ala Thr Pro His Asp Gly Thr Thr Leu Val Asn Met Val Asp Phe
165 170 175
Thr Asp Arg Phe Phe Asp Leu Gln Lys Ala Val Leu Glu Ala Ala Ala
180 185 190
Val Ala Ser Asn Val Pro Tyr Thr Ser Gln Val Tyr Asp Phe Lys Leu
195 200 205
Asp Gln Trp Gly Leu Arg Arg Gln Pro Gly Glu Ser Phe Asp His Tyr
210 215 220
Phe Glu Arg Leu Lys Arg Ser Pro Val Trp Thr Ser Thr Asp Thr Ala
225 230 235 240
Arg Tyr Asp Leu Ser Val Ser Gly Ala Glu Lys Leu Asn Gln Trp Val
245 250 255
Gln Ala Ser Pro Asn Thr Tyr Tyr Leu Ser Phe Ser Thr Glu Arg Thr
260 265 270
Tyr Arg Gly Ala Leu Thr Gly Asn His Tyr Pro Glu Leu Gly Met Glu
275 280 285
Phe Thr Lys Ala Val Val Cys Ala Pro Phe Leu Gly Ser Tyr Arg Asn
290 295 300
Pro Thr Leu Gly Ile Asp Asp Arg Trp Leu Glu Asn Asp Gly Ile Val
305 310 315 320
Asn Thr Val Ser Met Asn Gly Pro Lys Arg Gly Ser Ser Asp Arg Ile
325 330 335
Val Pro Tyr Asp Gly Thr Leu Lys Lys Gly Val Trp Asn Asp Met Gly
340 345 350
Thr Tyr Asn Val Asp His Ser Glu Ile Ile Gly Asn Asp Pro Asn Pro
355 360 365
Ser Phe Asp Ile Arg Ala Phe Tyr Leu Arg Leu Ala Glu Gln Leu Ala
370 375 380
Ser Leu Gln Pro
385
<210> 8
<211> 1164
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
gcatccctac gcgccaatga tgcaccgatt gtgcttctcc atgggtttac cggatgggga 60
cgagaggaaa tgtttggatt caagtattgg ggcggcgtgc gcggcgatat cgaacaatgg 120
ctgaacgaca acggttatcg aacgtatacg ctggcggtcg gaccgctctc aagcaactgg 180
gaccgggcgt gtgaagcgta tgctcagctt gtcggcggga cggtcgatta tggggcagcc 240
catgcggcaa agcacggcca tgcgcggttt ggccgcactt atcccggcct gttgccggaa 300
ttgaaaaggg gtggccgcat ccatatcatc gcccacagcc aaggggggca gacggcccgc 360
atgcttgtct cgctcctaga gaacggaagc caagaagagc gggagtacgc caaggcgcat 420
aacgtgtcgt tgtcaccgtt gtttgaaggt ggacatcatt ttgtgttgag tgtgacgacc 480
atcgccactc ctcatgacgg gacgacgctt gtcaacatgg ttgatttcac cgatcgcttt 540
tttgacttgc aaaaagcggt gttggaagcg gcggctgtcg ccagcaacgt gccgtacacg 600
agtcaagtat acgattttaa gctcgaccaa tggggactgc gccgccagcc gggtgaatcg 660
ttcgaccatt attttgaacg gctcaagcgc tcccctgttt ggacgtccac agataccgcc 720
cgctacgatt tatccgtttc cggagctgag aagttgaatc aatgggtgca agcaagcccg 780
aatacgtatt atttgagttt ctctacagaa cggacgtatc gcggagcgct cacaggcaac 840
cattatcccg aactcggaat gaatgcattc agcgcggtcg tatgcgctcc gtttctcggt 900
tcgtaccgca atccgacgct cggcattgac gaccgatggt tggagaacga tggcattgtc 960
aatacggttt ccatgaacgg tccaaagcgt ggatcaagcg atcggatcgt gccgtatgac 1020
gggacgttga aaaaaggggt ttggaatgat atgggaacgt acaacgttga ccatttggaa 1080
atcatcggcg ttgacccgaa tccgtcattt gatattcgcg ccttttattt gcggcttgcc 1140
gagcagttgg cgagcttgca gcct 1164
<210> 9
<211> 1164
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
gcatccctac gcgccaatga tgcaccgatt gtgcttctcc atgggtttac cggatgggga 60
cgagaggaaa tgtttggatt caagtattgg ggcggcgtgc gcggcgatat cgaacaatgg 120
ctgaacgaca acggttatcg aacgtatacg ctggcggtcg gaccgctctc aagcaactgg 180
gaccgggcgt gtgaagcgta tgctcagctt gtcggcggga cggtcgatta tggggcagcc 240
catgcggcaa agcacggcca tgcgcggttt ggccgcactt atcccggcct gttgccggaa 300
ttgaaaaggg gtggccgcat ccatatcatc gcccacagcc aaggggggca gacggcccgc 360
atgcttgtct cgctcctaga gaacggaagc caagaagagc gggagtacgc caaggcgcat 420
aacgtgtcgt tgtcaccgtt gtttgaaggt ggacatcatt ttgtgttgag tgtgacgacc 480
atcgccactc ctcatgacgg gacgacgctt gtcaacatgg ttgatttcac cgatcgcttt 540
tttgacttgc aaaaagcggt gttggaagcg gcggctgtcg ccagcaacgt gccgtacacg 600
agtcaagtat acgattttaa gctcgaccaa tggggactgc gccgccagcc gggtgaatcg 660
ttcgaccatt attttgaacg gctcaagcgc tcccctgttt ggacgtccac agataccgcc 720
cgctacgatt tatccgtttc cggagctgag aagttgaatc aatgggtgca agcaagcccg 780
aatacgtatt atttgagttt ctctacagaa cggacgtatc gcggagcgct cacaggcaac 840
cattatcccg aactcggaat gaatgcattc agcgcggtcg tatgcgctcc gtttctcggt 900
tcgtaccgca atccgacgct cggcattgac gaccgatggt tggagaacga tggcattgtc 960
aatacggttt ccatgaacgg tccaaagcgt ggatcaagcg atcggatcgt gccgtatgac 1020
gggacgttga aaaaaggggt ttggaatgat atgggaacgt acaacgttga ccattctgaa 1080
atcatcggcg ttgacccgaa tccgtcattt gatattcgcg ccttttattt gcggcttgcc 1140
gagcagttgg cgagcttgca gcct 1164
<210> 10
<211> 1164
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
gcatccctac gcgccaatga tgcaccgatt gtgcttctcc atgggtttac cggatgggga 60
cgagaggaaa tgtttggatt caagtattgg ggcggcgtgc gcggcgatat cgaacaatgg 120
ctgaacgaca acggttatcg aacgtatacg ctggcggtcg gaccgctctc aagcaactgg 180
gaccgggcgt gtgaagcgta tgctcagctt gtcggcggga cggtcgatta tggggcagcc 240
catgcggcaa agcacggcca tgcgcggttt ggccgcactt atcccggcct gttgccggaa 300
ttgaaaaggg gtggccgcat ccatatcatc gcccacagcc aaggggggca gacggcccgc 360
atgcttgtct cgctcctaga gaacggaagc caagaagagc gggagtacgc caaggcgcat 420
aacgtgtcgt tgtcaccgtt gtttgaaggt ggacatcatt ttgtgttgag tgtgacgacc 480
atcgccactc ctcatgacgg gacgacgctt gtcaacatgg ttgatttcac cgatcgcttt 540
tttgacttgc aaaaagcggt gttggaagcg gcggctgtcg ccagcaacgt gccgtacacg 600
agtcaagtat acgattttaa gctcgaccaa tggggactgc gccgccagcc gggtgaatcg 660
ttcgaccatt attttgaacg gctcaagcgc tcccctgttt ggacgtccac agataccgcc 720
cgctacgatt tatccgtttc cggagctgag aagttgaatc aatgggtgca agcaagcccg 780
aatacgtatt atttgagttt ctctacagaa cggacgtatc gcggagcgct cacaggcaac 840
cattatcccg aactcggaat gaatgcattc agcgcggtcg tatgcgctcc gtttctcggt 900
tcgtaccgca atccgacgct cggcattgac gaccgatggt tggagaacga tggcattgtc 960
aatacggttt ccatgaacgg tccaaagcgt ggatcaagcg atcggatcgt gccgtatgac 1020
gggacgttga aaaaaggggt ttggaatgat atgggaacgt acaacgttga ccatttggaa 1080
atcgaaggcg ttgacccgaa tccgtcattt gatattcgcg ccttttattt gcggcttgcc 1140
gagcagttgg cgagcttgca gcct 1164
<210> 11
<211> 1164
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
gcatccctac gcgccaatga tgcaccgatt gtgcttctcc atgggtttac cggatgggga 60
cgagaggaaa tgtttggatt caagtattgg ggcggcgtgc gcggcgatat cgaacaatgg 120
ctgaacgaca acggttatcg aacgtatacg ctggcggtcg gaccgctctc aagcaactgg 180
gaccgggcgt gtgaagcgta tgctcagctt gtcggcggga cggtcgatta tggggcagcc 240
catgcggcaa agcacggcca tgcgcggttt ggccgcactt atcccggcct gttgccggaa 300
ttgaaaaggg gtggccgcat ccatatcatc gcccacagcc aaggggggca gacggcccgc 360
atgcttgtct cgctcctaga gaacggaagc caagaagagc gggagtacgc caaggcgcat 420
aacgtgtcgt tgtcaccgtt gtttgaaggt ggacatcatt ttgtgttgag tgtgacgacc 480
atcgccactc ctcatgacgg gacgacgctt gtcaacatgg ttgatttcac cgatcgcttt 540
tttgacttgc aaaaagcggt gttggaagcg gcggctgtcg ccagcaacgt gccgtacacg 600
agtcaagtat acgattttaa gctcgaccaa tggggactgc gccgccagcc gggtgaatcg 660
ttcgaccatt attttgaacg gctcaagcgc tcccctgttt ggacgtccac agataccgcc 720
cgctacgatt tatccgtttc cggagctgag aagttgaatc aatgggtgca agcaagcccg 780
aatacgtatt atttgagttt ctctacagaa cggacgtatc gcggagcgct cacaggcaac 840
cattatcccg aactcggaat gaatgcattc agcgcggtcg tatgcgctcc gtttctcggt 900
tcgtaccgca atccgacgct cggcattgac gaccgatggt tggagaacga tggcattgtc 960
aatacggttt ccatgaacgg tccaaagcgt ggatcaagcg atcggatcgt gccgtatgac 1020
gggacgttga aaaaaggggt ttggaatgat atgggaacgt acaacgttga ccatttggaa 1080
atcatcggca atgacccgaa tccgtcattt gatattcgcg ccttttattt gcggcttgcc 1140
gagcagttgg cgagcttgca gcct 1164
<210> 12
<211> 1164
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
gcatccctac gcgccaatga tgcaccgatt gtgcttctcc atgggtttac cggatgggga 60
cgagaggaaa tgtttggatt caagtattgg ggcggcgtgc gcggcgatat cgaacaatgg 120
ctgaacgaca acggttatcg aacgtatacg ctggcggtcg gaccgctctc aagcaactgg 180
gaccgggcgt gtgaagcgta tgctcagctt gtcggcggga cggtcgatta tggggcagcc 240
catgcggcaa agcacggcca tgcgcggttt ggccgcactt atcccggcct gttgccggaa 300
ttgaaaaggg gtggccgcat ccatatcatc gcccacagcc aaggggggca gacggcccgc 360
atgcttgtct cgctcctaga gaacggaagc caagaagagc gggagtacgc caaggcgcat 420
aacgtgtcgt tgtcaccgtt gtttgaaggt ggacatcatt ttgtgttgag tgtgacgacc 480
atcgccactc ctcatgacgg gacgacgctt gtcaacatgg ttgatttcac cgatcgcttt 540
tttgacttgc aaaaagcggt gttggaagcg gcggctgtcg ccagcaacgt gccgtacacg 600
agtcaagtat acgattttaa gctcgaccaa tggggactgc gccgccagcc gggtgaatcg 660
ttcgaccatt attttgaacg gctcaagcgc tcccctgttt ggacgtccac agataccgcc 720
cgctacgatt tatccgtttc cggagctgag aagttgaatc aatgggtgca agcaagcccg 780
aatacgtatt atttgagttt ctctacagaa cggacgtatc gcggagcgct cacaggcaac 840
cattatcccg aactcggaat ggaatttacc aaagcggtcg tatgcgctcc gtttctcggt 900
tcgtaccgca atccgacgct cggcattgac gaccgatggt tggagaacga tggcattgtc 960
aatacggttt ccatgaacgg tccaaagcgt ggatcaagcg atcggatcgt gccgtatgac 1020
gggacgttga aaaaaggggt ttggaatgat atgggaacgt acaacgttga ccatttggaa 1080
atcatcggcg ttgacccgaa tccgtcattt gatattcgcg ccttttattt gcggcttgcc 1140
gagcagttgg cgagcttgca gcct 1164
<210> 13
<211> 1164
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
gcatccctac gcgccaatga tgcaccgatt gtgcttctcc atgggtttac cggatgggga 60
cgagaggaaa tgtttggatt caagtattgg ggcggcgtgc gcggcgatat cgaacaatgg 120
ctgaacgaca acggttatcg aacgtatacg ctggcggtcg gaccgctctc aagcaactgg 180
gaccgggcgt gtgaagcgta tgctcagctt gtcggcggga cggtcgatta tggggcagcc 240
catgcggcaa agcacggcca tgcgcggttt ggccgcactt atcccggcct gttgccggaa 300
ttgaaaaggg gtggccgcat ccatatcatc gcccacagcc aaggggggca gacggcccgc 360
atgcttgtct cgctcctaga gaacggaagc caagaagagc gggagtacgc caaggcgcat 420
aacgtgtcgt tgtcaccgtt gtttgaaggt ggacatcatt ttgtgttgag tgtgacgacc 480
atcgccactc ctcatgacgg gacgacgctt gtcaacatgg ttgatttcac cgatcgcttt 540
tttgacttgc aaaaagcggt gttggaagcg gcggctgtcg ccagcaacgt gccgtacacg 600
agtcaagtat acgattttaa gctcgaccaa tggggactgc gccgccagcc gggtgaatcg 660
ttcgaccatt attttgaacg gctcaagcgc tcccctgttt ggacgtccac agataccgcc 720
cgctacgatt tatccgtttc cggagctgag aagttgaatc aatgggtgca agcaagcccg 780
aatacgtatt atttgagttt ctctacagaa cggacgtatc gcggagcgct cacaggcaac 840
cattatcccg aactcggaat ggaatttacc aaagcggtcg tatgcgctcc gtttctcggt 900
tcgtaccgca atccgacgct cggcattgac gaccgatggt tggagaacga tggcattgtc 960
aatacggttt ccatgaacgg tccaaagcgt ggatcaagcg atcggatcgt gccgtatgac 1020
gggacgttga aaaaaggggt ttggaatgat atgggaacgt acaacgttga ccattctgaa 1080
atcatcggcg ttgacccgaa tccgtcattt gatattcgcg ccttttattt gcggcttgcc 1140
gagcagttgg cgagcttgca gcct 1164
<210> 14
<211> 1164
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
gcatccctac gcgccaatga tgcaccgatt gtgcttctcc atgggtttac cggatgggga 60
cgagaggaaa tgtttggatt caagtattgg ggcggcgtgc gcggcgatat cgaacaatgg 120
ctgaacgaca acggttatcg aacgtatacg ctggcggtcg gaccgctctc aagcaactgg 180
gaccgggcgt gtgaagcgta tgctcagctt gtcggcggga cggtcgatta tggggcagcc 240
catgcggcaa agcacggcca tgcgcggttt ggccgcactt atcccggcct gttgccggaa 300
ttgaaaaggg gtggccgcat ccatatcatc gcccacagcc aaggggggca gacggcccgc 360
atgcttgtct cgctcctaga gaacggaagc caagaagagc gggagtacgc caaggcgcat 420
aacgtgtcgt tgtcaccgtt gtttgaaggt ggacatcatt ttgtgttgag tgtgacgacc 480
atcgccactc ctcatgacgg gacgacgctt gtcaacatgg ttgatttcac cgatcgcttt 540
tttgacttgc aaaaagcggt gttggaagcg gcggctgtcg ccagcaacgt gccgtacacg 600
agtcaagtat acgattttaa gctcgaccaa tggggactgc gccgccagcc gggtgaatcg 660
ttcgaccatt attttgaacg gctcaagcgc tcccctgttt ggacgtccac agataccgcc 720
cgctacgatt tatccgtttc cggagctgag aagttgaatc aatgggtgca agcaagcccg 780
aatacgtatt atttgagttt ctctacagaa cggacgtatc gcggagcgct cacaggcaac 840
cattatcccg aactcggaat ggaatttacc aaagcggtcg tatgcgctcc gtttctcggt 900
tcgtaccgca atccgacgct cggcattgac gaccgatggt tggagaacga tggcattgtc 960
aatacggttt ccatgaacgg tccaaagcgt ggatcaagcg atcggatcgt gccgtatgac 1020
gggacgttga aaaaaggggt ttggaatgat atgggaacgt acaacgttga ccattctgaa 1080
atcatcggca atgacccgaa tccgtcattt gatattcgcg ccttttattt gcggcttgcc 1140
gagcagttgg cgagcttgca gcct 1164

Claims (4)

1.T1脂肪酶突变体,其特征在于,所述突变体的氨基酸序列为SEQ NO.2,SEQ NO.3,SEQNO.4,SEQ NO.5,SEQ NO.6或SEQ NO.7。
2.编码权利要求1所述T1脂肪酶突变体的基因,其特征在于,所述突变体的基因序列为SEQ NO.9,SEQ NO.10,SEQ NO.11,SEQ NO.12,SEQ NO.13或SEQ NO.14。
3.权利要求1所述T1脂肪酶突变体的应用,其特征在于,所述的脂肪酶突变体应用于洗涤剂、添加剂、食品、制药、造纸或生物能源中。
4.根据权利要求3所述T1脂肪酶突变体的应用,其特征在于,所述的脂肪酶突变体用于难熔油脂的改性。
CN201810017359.8A 2018-01-09 2018-01-09 T1脂肪酶突变体和应用 Active CN107916257B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810017359.8A CN107916257B (zh) 2018-01-09 2018-01-09 T1脂肪酶突变体和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810017359.8A CN107916257B (zh) 2018-01-09 2018-01-09 T1脂肪酶突变体和应用

Publications (2)

Publication Number Publication Date
CN107916257A CN107916257A (zh) 2018-04-17
CN107916257B true CN107916257B (zh) 2020-07-28

Family

ID=61891356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810017359.8A Active CN107916257B (zh) 2018-01-09 2018-01-09 T1脂肪酶突变体和应用

Country Status (1)

Country Link
CN (1) CN107916257B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109666661A (zh) * 2018-12-31 2019-04-23 苏州埃斯腾特生物科技有限公司 去除纸浆中胶粘物的生物酶制剂
CN113943721B (zh) * 2021-11-11 2023-05-02 湖南福来格生物技术有限公司 一种脂肪酶突变体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071726A1 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Methods to inhibit infectious agent transmission during xenotransplantation
CN1404401A (zh) * 2000-01-10 2003-03-19 马克西根控股公司 G-csf偶联物
CN102439044A (zh) * 2009-04-22 2012-05-02 阿特根公司 通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法
CN102660517A (zh) * 2011-12-08 2012-09-12 上海交通大学 热稳定性提高的脂肪酶突变体及其构建方法
CN103627685A (zh) * 2013-11-20 2014-03-12 华南理工大学 一种活性提高的偏甘油酯脂肪酶突变体及其应用
CN105886492A (zh) * 2016-06-06 2016-08-24 华南理工大学 一种固定化脂肪酶及其制备方法和在催化合成甘油酯型pufa中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071726A1 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Methods to inhibit infectious agent transmission during xenotransplantation
CN1404401A (zh) * 2000-01-10 2003-03-19 马克西根控股公司 G-csf偶联物
CN102439044A (zh) * 2009-04-22 2012-05-02 阿特根公司 通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法
CN102660517A (zh) * 2011-12-08 2012-09-12 上海交通大学 热稳定性提高的脂肪酶突变体及其构建方法
CN103627685A (zh) * 2013-11-20 2014-03-12 华南理工大学 一种活性提高的偏甘油酯脂肪酶突变体及其应用
CN105886492A (zh) * 2016-06-06 2016-08-24 华南理工大学 一种固定化脂肪酶及其制备方法和在催化合成甘油酯型pufa中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
表面活性剂对T1脂肪酶活力的影响;唐庆芸等;《现代食品科技》;20161130;第33卷(第3期);第179-183、170页 *

Also Published As

Publication number Publication date
CN107916257A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
CN103525790B (zh) 一种优化的耐高温甘露聚糖酶MAN5gy及其制备方法和应用
CN107739734A (zh) 一种酶活提高的谷氨酰胺转氨酶突变体
CN114752581B (zh) 一种α-半乳糖苷酶突变体及其应用
CN105400750B (zh) 一种深海新型低温耐盐酯酶及应用
Huang et al. Directed evolution of α-amylase from Bacillus licheniformis to enhance its acid-stable performance
CN113684198B (zh) 一种提高纤维素酶催化效率的方法及突变体5i77-m2
CN113801862B (zh) 一种海洋链霉菌磷脂酶d突变体及其重组表达菌株的制备方法
Chen et al. Overexpression and mutation of a novel lipase from Serratia marcescens L1 in Escherichia coli
JP5178517B2 (ja) 変異型酵素の設計法、調製法、及び変異型酵素
CN107916257B (zh) T1脂肪酶突变体和应用
CN111676210B (zh) 一种提高纤维素酶活性的方法及纤维素酶突变体5i77-m和应用
CN110055233B (zh) 一种热稳定性提高的MTSase突变体及其应用
CN109576240B (zh) 一种淀粉蔗糖酶突变体及其制备方法与应用
CN112301014B (zh) 一种热稳定性提高的酯酶突变体及其应用
CN107384891A (zh) 一种深海细菌来源新型耐盐碱性酯酶及应用
CN108359655B (zh) 一种热稳定性高的脂肪酶突变体TDL-mut及其编码基因
CN112226422B (zh) 一种活性提高的EstWY酶突变体
CN111139229B (zh) 一种新型gdsl家族脂类水解酶eii-2及其编码基因与应用
CN119570765A (zh) 用于合成l-肌肽的氨肽酶及其应用
Lu et al. Cloning, expression and improvement of catalytic activity of alginate lyase by site-directed mutation
Ningsih et al. Cloning and expression of gene encoding lipase from local isolate Bacillus cereus isolated from compost Jambangan Indonesia
CN114836406B (zh) 一种催化活力提高的琼胶酶突变体及其应用
CN114395543B (zh) 一种海藻糖合酶突变体及其应用
CN110484525A (zh) 一种耐热n-乙酰氨基葡萄糖脱乙酰酶及其编码基因与应用
CN101402947A (zh) 一种酯酶新基因及其重组表达体系

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant